

1 March 2023

Diaceutics PLC
("Diaceutics" or "the Company")

PDMR Shareholding/Share Incentive Plan

[Diaceutics PLC](#), (AIM: DXRX), a leading technology and solutions provider to the pharmaceutical industry, has been notified that on 28 February 2023, Global Shares Trustees (UK) Limited and Zedra Trust Company (Guernsey) Limited, the trustees of the Global Diaceutics plc 2020 Employee Benefit Trust, have purchased ordinary shares ("Shares") on behalf of Stefan McDonald, Susanne Munksted, Jordan Clark, Julie Browne and Nick Roberts (PDMRs), in respect of their purchase of Shares pursuant to the Company's UK and Global Share Incentive Plan ("the SIP Schemes") for employees. These purchases will be made each month until further notice.

In accordance with the SIP Schemes, the Company has matched these purchases with a matched share award over an equivalent number of Shares purchased by the employee, in the proportion of 1:1.

Enquiries:

Diaceutics PLC

Nick Roberts, Chief Financial Officer

Via Alma PR

Stifel Nicolaus Europe Limited (Nomad & Broker)

Ben Maddison
Stewart Wallace
Nick Adams

Tel: +44 (0)20 7710 7600

Alma PR

Caroline Forde
Kieran Breheny
Matthew Young
Kinvara Verdon

Tel: +44(0)20 3405 0205
diaceutics@almapr.co.uk

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharmaceutical and life science companies with solutions and technology for the commercialisation of their precision medicines, enabled by the proprietary DXRX platform.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, utilising a global network of affiliate laboratories to deliver multiple pipelines of real-world healthcare data insights, advisory services and innovative platform enabled solutions.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014		
1 Details of the person discharging managerial responsibilities/person closely associated		
a.	Name	Susanne Munksted
2 Reason for notification		
a.	Position/Status	Chief Precision Medicine Officer and PDMR
b.	Initial notification/ Amendment	Initial
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a.	Name	Diaceutics PLC

b.	LEI	213800VEWQBB39ZB8J81										
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted												
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.002 each ISIN: GB00BJQTVG64										
b.	Nature of the transaction	Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Global Share Incentive Plan ("SIP")										
c.	Price(s) and volume(s)	Share purchase: <table border="1" style="margin-left: 40px;"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>1.154 p</td> <td>133</td> </tr> <tr> <td colspan="2">Conditional share award:</td> </tr> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> <tr> <td>Nil</td> <td>133</td> </tr> </tbody> </table>	Price(s)	Volume(s)	1.154 p	133	Conditional share award:		Price(s)	Volume(s)	Nil	133
Price(s)	Volume(s)											
1.154 p	133											
Conditional share award:												
Price(s)	Volume(s)											
Nil	133											
e.	Date of the transaction	Share purchase and Conditional share award: 28 February 2023										
f.	Place of the transaction	Share Purchase: AIM Market of the London Stock Exchange Conditional share award: Off-Market										

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014						
1 Details of the person discharging managerial responsibilities/person closely associated						
a.	Name	Jordan Clark				
2 Reason for notification						
a.	Position/Status	Chief Commercial Officer and PDMR				
b.	Initial notification/ Amendment	Initial				
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a.	Name	Diaceutics PLC				
b.	LEI	213800VEWQBB39ZB8J81				
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.002 each ISIN: GB00BJQTVG64				
b.	Nature of the transaction	Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP")				
c.	Price(s) and volume(s)	Share purchase: <table border="1" style="margin-left: 40px;"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td> </td> <td> </td> </tr> </tbody> </table>	Price(s)	Volume(s)		
Price(s)	Volume(s)					

		<table border="1"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>1.154 p</td> <td>130</td> </tr> <tr> <td colspan="2">Matched share award:</td> </tr> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>1.154 p</td> <td>130</td> </tr> </table>	Price(s)	Volume(s)	1.154 p	130	Matched share award:		Price(s)	Volume(s)	1.154 p	130
Price(s)	Volume(s)											
1.154 p	130											
Matched share award:												
Price(s)	Volume(s)											
1.154 p	130											
e.	Date of the transaction	Share purchase and Matched Share award: 28 February 2023										
f.	Place of the transaction	Share Purchase and Matched Share Award: AIM Market of the London Stock Exchange										

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014												
1 Details of the person discharging managerial responsibilities/person closely associated												
a.	Name	Julie Browne										
2 Reason for notification												
a.	Position/Status	Chief Operations Officer and PDMR										
b.	Initial notification/ Amendment	Initial										
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor												
a.	Name	Diaceutics PLC										
b.	LEI	213800VEWQBB39ZB8J81										
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted												
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.002 each ISIN: GB00BJQTGV64										
b.	Nature of the transaction	Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP")										
c.	Price(s) and volume(s)	Share purchase: <table border="1"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>1.154 p</td> <td>130</td> </tr> <tr> <td colspan="2">Matched share award:</td> </tr> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>1.154 p</td> <td>130</td> </tr> </table>	Price(s)	Volume(s)	1.154 p	130	Matched share award:		Price(s)	Volume(s)	1.154 p	130
Price(s)	Volume(s)											
1.154 p	130											
Matched share award:												
Price(s)	Volume(s)											
1.154 p	130											
e.	Date of the transaction	Share purchase and Matched Share award: 28 February 2023										

f.	Place of the transaction	Share Purchase and Matched Share Award: AIM Market of the London Stock Exchange
----	--------------------------	---

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014										
1 Details of the person discharging managerial responsibilities/person closely associated										
a.	Name	Nick Roberts								
2 Reason for notification										
a.	Position/Status	Chief Finance Officer and PDMR								
b.	Initial notification/ Amendment	Initial								
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor										
a.	Name	Diaceutics PLC								
b.	LEI	213800VEWQBB39ZB8J81								
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted										
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.002 each ISIN: GB00BJQTGV64								
b.	Nature of the transaction	Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP")								
c.	Price(s) and volume(s)	Share purchase: <table border="1" style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>1.154 p</td> <td>130</td> </tr> </tbody> </table> Matched share award: <table border="1" style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>1.154 p</td> <td>130</td> </tr> </tbody> </table>	Price(s)	Volume(s)	1.154 p	130	Price(s)	Volume(s)	1.154 p	130
Price(s)	Volume(s)									
1.154 p	130									
Price(s)	Volume(s)									
1.154 p	130									
e.	Date of the transaction	Share purchase and Matched Share award: 28 February 2023								
f.	Place of the transaction	Share Purchase and Matched Share Award: AIM Market of the London Stock Exchange								

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to

share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHSSLFDFEDSEID